Hikma Pharmaceuticals (OTCMKTS:HKMPF) Upgraded to Hold at Barclays

Barclays upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from a strong sell rating to a hold rating in a report published on Tuesday,Zacks reports.

Separately, Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Hikma Pharmaceuticals presently has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at $22.19 on Tuesday. The stock has a fifty day simple moving average of $21.52 and a two-hundred day simple moving average of $19.63. Hikma Pharmaceuticals has a 12 month low of $16.34 and a 12 month high of $25.34. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.82 and a quick ratio of 1.06.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.